Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charness, M. E.
Right arrow Articles by Scheinman, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charness, M. E.
Right arrow Articles by Scheinman, M. M.
NEUROLOGY 1984;34:669
© 1984 American Academy of Neurology

Frequent neurologic toxicity associated with amiodarone therapy

Michael E. Charness, MD, Fred Morady, MD and Melvin M. Scheinman, MD

From the Departments of Neurology (Dr. Charness) and Medicine (Drs. Morady and Scheinman), University of California, San Francisco, CA.

Fifty-four consecutive patients were treated with amiodarone for symptomatic ventricular tachycardia or ventricular fibrillation refractory to treatment with conventional antiarrhythmic drugs. A reversible neurologic syndrome of tremor, ataxia, and occasionally peripheral neuropathy without nystagmus, dizziness, encephalopathy, or long-tract signs developed in 54% of the patients and was the most common reason for altering or discontinuing drug therapy. Neurologic side effects improved or resolved within 2 days to 4 weeks of decreasing or discontinuing amiodarone. Frequent neurologic toxicity is a hitherto undescribed complication of amiodarone therapy. Wider recognition of this syndrome will avoid unnecessary and costly diagnostic evaluation.

Address correspondence and reprint requests to Dr. Charness, Department of Neurology, Room 794, Moffitt Hospital, University of California, San Francisco, CA 94143.

Accepted for publication September 14, 1983.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
C. F. Orr and J. E. Ahlskog
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol, July 1, 2009; 66(7): 865 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. S. Willis and A. M. Lugo
Amiodarone-induced neurotoxicity
Am. J. Health Syst. Pharm., March 15, 2009; 66(6): 567 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Age AgeingHome page
J. V. Hindle, A. Ibrahim, and R. Ramaraj
Ataxia caused by amiodarone in older people
Age Ageing, May 1, 2008; 37(3): 347 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. J. BARRY and K. FRANKLIN
Amiodarone-Induced Delirium
Am J Psychiatry, July 1, 1999; 156(7): 1119 - 1119.
[Full Text]

Home page
 ANN INTERN MEDHome page
R. G. TROHMAN, D. CASTELLANOS, A. CASTELLANOS, and K. M. KESSLER
Amiodarone-lnduced Delirium
Ann Intern Med, January 1, 1988; 108(1): 68 - 69.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
P. R. Palakurthy, V. Iyer, and R. J. Meckler
Unusual Neurotoxicity Associated With Amiodarone Therapy
Arch Intern Med, May 1, 1987; 147(5): 881 - 884.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by AAN Enterprises, Inc.